RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice

[1]  M. de la Guardia,et al.  Modulating tumor hypoxia by nanomedicine for effective cancer therapy , 2018, Journal of cellular physiology.

[2]  N. Zarghami,et al.  Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[3]  Fengyong Liu,et al.  Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[4]  N. Zarghami,et al.  Tumor vascular infarction: prospects and challenges , 2017, International Journal of Hematology.

[5]  C. Hartmann,et al.  Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation , 2016, Cell Death and Disease.

[6]  V. Sexl,et al.  Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation , 2016, Molecular Pharmacology.

[7]  G C P van Zundert,et al.  The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes. , 2016, Journal of molecular biology.

[8]  E. Wardelmann,et al.  NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor , 2016, Oncotarget.

[9]  A. Üren,et al.  YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model , 2015, Oncotarget.

[10]  D. Levy,et al.  STAT3 regulated ARF expression suppresses prostate cancer metastasis , 2015, Nature Communications.

[11]  Yang Zhang,et al.  The I-TASSER Suite: protein structure and function prediction , 2014, Nature Methods.

[12]  A. Gruber,et al.  Contributions of thrombin targets to tissue factor‐dependent metastasis in hyperthrombotic mice , 2014, Journal of thrombosis and haemostasis : JTH.

[13]  Robson Q. Monteiro,et al.  Activation of blood coagulation in cancer: implications for tumour progression , 2013, Bioscience reports.

[14]  Yilin Zhao,et al.  Targeting the Vasculature of Colorectal Carcinoma with a Fused Protein of (RGD)3-tTF , 2013, TheScientificWorldJournal.

[15]  D. Missiakas,et al.  Coagulases as Determinants of Protective Immune Responses against Staphylococcus aureus , 2012, Infection and Immunity.

[16]  M. Bar‐eli,et al.  PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. , 2011, Cancer research.

[17]  Andreas P. Eichenberger,et al.  Definition and testing of the GROMOS force-field versions 54A7 and 54B7 , 2011, European Biophysics Journal.

[18]  D. Missiakas,et al.  Contribution of Coagulases towards Staphylococcus aureus Disease and Protective Immunity , 2010, PLoS pathogens.

[19]  Shuang Liu.  Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. , 2009, Bioconjugate chemistry.

[20]  Walter Heindel,et al.  Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. , 2009, Blood.

[21]  Ying-ying Lin,et al.  A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model , 2008, Journal of Zhejiang University SCIENCE B.

[22]  S. Karpatkin,et al.  Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. , 2006, Cancer cell.

[23]  W. Ruf,et al.  Thrombin generation and the pathogenesis of cancer. , 2006, Seminars in thrombosis and hemostasis.

[24]  W. Bode,et al.  Fibrinogen Substrate Recognition by Staphylocoagulase·(Pro)thrombin Complexes* , 2006, Journal of Biological Chemistry.

[25]  W. Bode,et al.  Structural Basis for Reduced Staphylocoagulase-mediated Bovine Prothrombin Activation* , 2006, Journal of Biological Chemistry.

[26]  Thorsten Persigehl,et al.  Inhibition of Tumor Growth by RGD Peptide–Directed Delivery of Truncated Tissue Factor to the Tumor Vasculature , 2005, Clinical Cancer Research.

[27]  W. Berdel,et al.  Inhibition of Tumor Growth by RGD Peptide Directed Delivery of Truncated Tissue Factor to the Tumor Vasculature. , 2004 .

[28]  W. Bode,et al.  The staphylocoagulase family of zymogen activator and adhesion proteins , 2004, Cellular and Molecular Life Sciences CMLS.

[29]  Xiaofeng Jiang,et al.  Formation of tissue factor–factor VIIa–factor Xa complex promotes cellular signaling and migration of human breast cancer cells , 2004, Journal of thrombosis and haemostasis : JTH.

[30]  R. Huber,et al.  Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation , 2003, Nature.

[31]  L. Khawli,et al.  Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. , 2003, Cancer research.

[32]  R. Santucci,et al.  Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. , 2002, Cancer research.

[33]  Thilo Stehle,et al.  Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand , 2002, Science.

[34]  S. Coughlin,et al.  Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Ran,et al.  Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. , 1998, Cancer research.

[36]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[37]  Grietje Molema,et al.  Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature , 1997, Science.

[38]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[39]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[40]  P. Kollman,et al.  Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .

[41]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[42]  H. Berendsen,et al.  A consistent empirical potential for water–protein interactions , 1984 .

[43]  R. Huber,et al.  Induction of the bovine trypsinogen—trypsin transition by peptides sequentially similar to the N‐terminus of trypsin , 1976, FEBS letters.

[44]  M. Drummond,et al.  Staphylocoagulase as a hemostatic agent. , 1969, The Yale journal of biology and medicine.

[45]  H. Reid,et al.  The paradox in therapeutic defibrination. , 1968, Lancet.

[46]  J. Jeljaszewicz,et al.  Intravascular Coagulation and Fibrinolysis by Stapliylocoagiilase. Comparison with Thrombin , 1965, Thrombosis and Haemostasis.

[47]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[48]  H. Kosmehl,et al.  Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. , 2001, Cancer research.

[49]  J. Soulier,et al.  [Effects of the injection of staphylocoagulase in rabbits. Attempt to prevent the defibrination syndrome]. , 1967, Nouvelle revue francaise d'hematologie.